Amifostine-induced fever: case report and review of the literature.
Amifostine, also known as WR-2721 (S-2-(3-aminopropylamino)-ethylphosphorothioic acid), is an organic thiophosphate cytoprotective agent used to reduce the frequency of severe xerostomia in patients with cancer undergoing postoperative radiation of the head and neck. A 56-year-old Caucasian man who received concomitant chemotherapy and radiation for head and neck cancer developed fever concurrent with the administration of amifostine. To our knowledge, this is the first case report that demonstrates the occurrence of fever with low-dose amifostine therapy without the manifestation of accompanying rash or hypotension. Patients receiving amifostine who develop only fever should be evaluated for an adverse drug reaction, as well as for sepsis and fevers of neutropenia, and it may be necessary to discontinue the drug. Recognition of amifostine as the cause of this adverse event may prevent the cost and inconvenience of a hospital admission.
Boehme
Sabrina
S
St. Luke's Regional Medical Center, Mountain States Tumor Institute, Boise, Idaho 83712, USA.
Wilson
David B
DB
D004999:Amifostine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy; D003131:Combined Modality Therapy; D005334:Fever / Q000139:chemically induced* / Q000150:complications; D006258:Head and Neck Neoplasms / Q000628:therapy; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011355:Prodrugs; D011837:Radiation-Protective Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D014987:Xerostomia / Q000188:drug therapy
D011355:Prodrugs; D011837:Radiation-Protective Agents; D004999:Amifostine